MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion...
Akeso’s AK111 Achieves Key Efficacy Milestones in Phase III Trial for Plaque Psoriasis
Akeso Biopharma (HKG: 9926), based in China, has announced that its pivotal Phase III clinical...
Sichuan Kelun-Biotech to Present Promising Phase II Results for SKB264 in mTNBC at SABCS 2023
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...
TG ImmunoPharma Secures U.S. FDA IND Approval for Promising mAb TGI-5 Targeting Multiple Cancers
TG ImmunoPharma Co., Ltd, based in China, has announced that it has received Investigational New...
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of...
Simcere Secures NMPA Approval for Edaravone Sublingual Tablets Targeting Post-Stroke Cognitive Impairment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has received clinical trial approval from the National...
Everest Medicines Reports Positive Phase III Results for Velsipity in Ulcerative Colitis
Everest Medicines (HKG: 1952), based in China, has announced positive topline results from a multi-center...
Acotec Secures FDA IDE Approval for AcoArt Litos Paclitaxel-Coated Balloon Catheter
Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received Investigational Device Exemption (IDE)...
Perpetual Medicines Launches with $8 Million Seed Round, Led by Chengwei Capital
Perpetual Medicines, a biotech firm with operations in Shanghai and Boston, has officially launched, announcing...
Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China
Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its...
Novocure Restructures and Prioritizes Pipeline Amid Anticipated NSCLC Approval
Novocure (NASDAQ: NVCR), a Switzerland-based developer of Tumor Treating Fields (TTFields) cancer therapeutic technology that...
AbbVie’s Telisotuzumab-Vedotin Shows Promising Results in NSCLC Phase 2 Trial
AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class...
Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic...
Jiangsu Hengrui Receives NMPA Approval for Esophageal Cancer and Breast Cancer Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
Asieris Pharmaceuticals’ Hexvix for Bladder Cancer Accepted for Review by China’s NMPA
Asieris Pharmaceuticals (SHA: 688176), a specialist in urogenital cancer based in China, has announced that...
Jiangxi Jemincare’s KRAS Inhibitor Earns Breakthrough Designation from China’s CDE for NSCLC
The China Center for Drug Evaluation (CDE) website has indicated that Jiangxi Jemincare Group’s proprietary...
Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm...
Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China
The China Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Lunsumio...
China’s CDE Expands Market Approval Services with Two New Regional Windows
The China Center for Drug Evaluation (CDE) has announced the establishment of two additional external...
Sinocelltech’s PD-1 Inhibitor SCT-I10A for HNSCC Accepted for NMPA Review
Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that its market approval...